ライフサイエンスコーパス: bromelain

1 f zingibain and had no significant effect on bromelain.

2 rongly correlated with those of SA-CAP-1 and bromelain.

3 nded to 2% to 3% of the reactivity seen with bromelain.

4 tin, AcCYS1, inhibited (>95%) stem and fruit bromelain.

5 erase to proteolysis by papain, trypsin, and bromelain.

6 Of 52 CCD-positive sera (bromelain, 1.01-59.6 kilounits of antigen per liter [kUA

7 Bromelain, a mixture of cysteine proteases from pineappl

8 We show that bromelain, a mixture of cysteine proteases from pineappl

9 vestigate the possible therapeutic effect of bromelain, a proteolytic extract obtained from pineapple

10 he activity of four plant proteases (papain, bromelain, actinidin and zingibain) and three microbial

11 equence homology with other members (papain, bromelain, actinidin, protease omega, etc.) of this fami

12 Bromelain also blocked signaling induced by carbachol an

13 Surprisingly, bromelain also did not block serovar Typhimurium-induced

14 Bromelain also inhibited PMA-induced IL-2, IFN-gamma, an

15 Bromelain also prevented secretory changes caused by pro

16 all than hydrolysates generated with papain, bromelain and FP400.

17 test (BAT) with both venoms as well as with bromelain and horseradish peroxidase (HRP) or recombinan

18 mice exposed to cysteine proteases, such as bromelain and papain, as a model for allergens.

19 0.8-3.2mM inhibited the activity of papain, bromelain and zingibain, iso-AA acted as an inhibitor of

20 Protease preparations from plant (papain and bromelain) and fungal (FP400 and FPII) sources were used

21 protease preparations from plant (papain and bromelain) and fungal (FP400 and FPII) sources.

22 and a BAT (Flow2 CAST) with venom extracts, bromelain, and HRP was performed.

23 teine proteases (clan CA, family C1) papain, bromelain, and human cathepsins L, V, K, S, F, B, and fi

24 umami sensor outputs were characteristic of bromelain- and Flavourzyme-produced hydrolysates, compar

25 In this study, purified HA trimers (bromelain-cleaved HA [BHA]) are used to examine the prop

26 Bromelain did not act on ERK-2 directly, as it also inhi

27 solvents, hot alkali, or proteases (papain, bromelain) diminished the adsorption rates of the biosor

28 Our results show that bromelain dose dependently blocks serovar Typhimurium-in

29 e inhibitory potency of AcCYS1 against fruit bromelain during fruit ripening to increase tissue prote

30 n after agar extraction was hydrolysed using bromelain (enzyme activity=119,325 U/g) at 0-20% (w/w) f

31 t functions, including plant enzymes papain, bromelain, ficin, and mammalian lysosomal cathepsins B a

32 s produced by different proteases (Alcalase, bromelain, Flavourzyme, Protamex, Protease A"Amano"2, Pr

33 tions for the production of eb-SWPH were 10% bromelain for 3h, which resulted in a 38.15% yield and a

34 tions from plant and fungal sources (papain, bromelain, FP400 and FPII) were used to hydrolyse plasma

35 city (ORAC) compared to those generated with bromelain, FP400 and FPII.

36 interactions that was prepared from purified bromelain glycopeptides and human serum albumin.

37 h NTT was required to inhibit fruit and stem bromelain (>95%), whereas its removal decreased inhibiti

38 sIgE antibodies to MUXF3 CCD, bromelain, HRP, rApi m 1, and rVes v 5 were determined,

39 BAT with bromelain/HRP showed a sensitivity of 50%/81% and a spec

40 gE directed against CCDs was investigated by bromelain IgE inhibition and concanavalin A binding assa

41 Despite bromelain inhibition of serovar Typhimurium-induced MAP

42 Data also confirm that bromelain is a novel inhibitor of MAP kinase signaling p

43 The results indicate that bromelain is a novel inhibitor of T cell signal transduc

44 ly poor inhibitors of the cysteine protease, bromelain, of pineapple (Ananas comosus).

45 In this study, we examined the effect of bromelain on Salmonella enterica serovar Typhimurium inf

46 The effect of bromelain pretreatment on short-circuit responses to Esc

47 Bromelain prevents intestinal fluid secretion mediated b

48 piglets challenged with this infection after bromelain prophylaxis.

49 Binding correlated with antibody binding to bromelain (r = 0.61) and to all blank ImmunoCAPs (r > 0.

50 g to SA-CAP-1 correlated with IgE binding to bromelain (r = 0.68) and was completely abolished by ser

51 In this regard, stem bromelain (SBM), a pharmacologically active member of th

52 An enzymatic bromelain seaweed protein hydrolysate (eb-SWPH) was char

53 This phase was obliterated for bromelain-treated virions with the ectodomains removed.

54 rvirens pollen extracts is mainly related to bromelain-type epitopes of a newly identified cypress PG

55 Bromelain was 62% effective in preventing heat-labile en

56 The inhibitory activity of bromelain was dependent on its proteolytic activity, as

57 The efficacy of bromelain was not caused by reduced tissue viability res

58 The benefit of the proteolytic agent bromelain, which degrades enterocyte receptors for enter